Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 6/20 | 0.51 |
| ▸ | CCR2 | P41597 | 4/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7492984 | 0.88 | CCR2 (0.57) | PLA2G10CCR2ALDH1A1TSHRDAO | |
| SCHEMBL2460494 | 0.81 | NOD2 (0.56) | CCR2F10ALDH1A1TSHR | |
| SCHEMBL4102690 | 0.79 | PLA2G10 (0.49) | PLA2G10CCR2F10ALDH1A1TSHR | |
| SCHEMBL30310782 | 0.76 | PLA2G10 (0.40) | PLA2G10CCR2F10MCL1 | |
| SCHEMBL1573798 | 0.75 | PLA2G10 (0.78) | PLA2G10CCR2F10F2 | |
| SCHEMBL8584166 | 0.74 | CCR2 (0.55) | PLA2G10CCR2ALDH1A1TSHRDAO | |
| SCHEMBL29572644 | 0.74 | ALDH1A1 (0.52) | CCR2F10ALDH1A1TSHRSRD5A1 | |
| SCHEMBL5186269 | 0.74 | PLA2G10 (0.51) | PLA2G10CCR2F10ALDH1A1TSHR | |
| SCHEMBL28109529 | 0.74 | PLA2G10 (0.64) | PLA2G10CCR2F10ALDH1A1MCL1 | |
| SCHEMBL29604362 | 0.74 | ALDH1A1 (0.47) | PLA2G10ALDH1A1TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6214856-B1 | TREATING NEURODEGENERATIVE DISORDERS, E.G., ALZHEIMER'S DISEASE, STROKES, TRAUMATIC BRAIN INJURY; ANTIISCHEMIC AGENTS; MUSCULAR DYSTROPHY; ALSO CATARACTS; PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION | 2001-04-10 | — | — | US | disclosed |